Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.41 |
| ▸ | KDM5A | P29375 | 5/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234043 | 0.86 | MAPT (0.50) | MAPTZDHHC20ZDHHC2 | |
| SCHEMBL25414195 | 0.83 | S1PR2 (0.46) | S1PR2S1PR1S1PR3S1PR5GGPS1 | |
| SCHEMBL25914044 | 0.83 | S1PR2 (0.46) | S1PR2S1PR1S1PR3S1PR5GGPS1 | |
| SCHEMBL25320265 | 0.83 | MAPT (0.47) | MAPTKDM4CKDM5APHF8ZDHHC20 | |
| SCHEMBL31271978 | 0.78 | DNM1 (0.40) | MAPTKDM4CKDM5APHF8KDM5C | |
| SCHEMBL31271923 | 0.78 | DNM1 (0.40) | MAPTKDM4CKDM5APHF8KDM5C | |
| SCHEMBL9101455 | 0.77 | MAPT (0.59) | MAPTZDHHC20ZDHHC2FDPS | |
| SCHEMBL31196411 | 0.77 | MAPT (0.41) | MAPTZDHHC20ZDHHC2 | |
| SCHEMBL31272298 | 0.75 | CES2 (0.39) | MAPTKDM4CKDM5APHF8 | |
| SCHEMBL31271866 | 0.75 | CES2 (0.39) | MAPTKDM4CKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102260-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING ANGIOPOIETIN LIKE 3 (ANGPTL3) | EDITAS MEDICINE, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| US-20250059131-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | ACUITAS THERAPEUTICS INC (CA) | 2025-02-20 | — | — | US | disclosed |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2024-10-29 | — | — | US | disclosed |
| EP-4448482-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448485-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2024-10-23 | — | — | EP | disclosed |
| CN-118647599-A | Fluoro cationic lipids for lipid nanoparticles | 爱康泰生治疗公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118647600-A | Lipids for lipid nanoparticle formulations | 爱康泰生治疗公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114937-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114937-A2 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | MAPT 14/4885S1PR2 181/4885S1PR1 169/4885 |
| US-20250059131-A1 | FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES | PHOSPHO1, NPC1, SGMS1 | MAPT 19/4885S1PR2 264/4885S1PR1 191/4885 |
| US-20250188020-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | MAPT 14/4885S1PR2 181/4885S1PR1 169/4885 |
| US-12129223-B2 | Lipids for use in lipid nanoparticle formulations | PHOSPHO1, SGMS1, NPC1 | MAPT 14/4885S1PR2 181/4885S1PR1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.